您的当前位置:首页 > 行业数据 > AK112在EGFRTKI耐药NSCLC实现与国内主要在研疗法可比的疗效
图片属性
图片格式:PNG 图片大小:363KB 图片尺寸:2304*1346
同报告图片
 / 4
AK112在EGFRTKI耐药NSCLC实现与国内主要在研疗法可比的疗效_第1页
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
AK112在EGFRTKI耐药NSCLC实现与国内主要在研疗法可比的疗效_第2页
fCDlk4HniYwgICAgICAgfCDljaDmr5QgIHwKfC0tLS0tLS0tLS0tLXwtLS0tLS18CnwgQkFJIFpFIEFOICB8IDM1JSAgfAp8IFRZVllUICAgICAgfCAyNSUgIHwKfCBBTCBSVUkgS0EgIHwgMTUlICB8CnwgS0VZVFJVREEgICB8IDEwJSAgfAp8IFRVTyBZSSAgICAgfCA1JSAgIHwKfCBIQU4gU0hJIFpIVUFORyB8IDMlICB8CnwgVEVDRU5UUklRICB8IDIlICAgfAp8IE9QRElWTyAgICAgfCAyJSAgIHwKfCBBTiBOSSBLRSAgIHwgMSUgICB8CnwgRU4gV0VJIERBICB8IDElICAgfAp8IE9USEVSUyAgICAgfCAxJSAgIHwKCui1hOaWmeadpea6kO+8mklRVklB77yM5Lit5rOw6K+B5Yi456CU56m25omA
AK112在EGFRTKI耐药NSCLC实现与国内主要在研疗法可比的疗效_第3页
AK112在EGFRTKI耐药NSCLC实现与国内主要在研疗法可比的疗效_第4页
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
AK112在EGFRTKI耐药NSCLC实现与国内主要在研疗法可比的疗效_第5页
所属报告: 康方生物-港股公司研究报告-双特异抗体龙头国际化之路现胜利曙光-240621(37页).pdf
打包全文图表

相关数据

客服
商务合作
小程序
服务号
折叠